Bliss Biopharmaceutical

Focus: Bliss Biopharmaceutical is a China-based biotech company specializing in antibody-drug conjugates (ADCs) for oncology indications. The company is in early-stage clinical development with a focus on HER2-positive and solid tumor therapeutics.

Unknown

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Bliss Biopharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Bliss Biopharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BB-1705

Solid Tumor

Phase 1

Clinical Trials (1)

NCT05217693A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

Phase 1

Help build intelligence for Bliss Biopharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized ADC platform in oncology offers deep technical expertise in a high-growth modality with multiple programs in active development
Early-stage growth stage with 10 active job openings across R&D, manufacturing, and quality functions signals expansion phase
Access to China's biotech ecosystem and potential Asia-Pacific market opportunities for emerging therapeutic platforms

Watch Out For

Pre-revenue status with no disclosed funding, cash position, or financial metrics creates uncertainty around runway and long-term stability
Early-stage pipeline (3 Phase 1 programs, 1 Phase 2) with no Phase 3 data or FDA-track record introduces significant clinical and regulatory risk
Minimal publication record (0 publications) and no disclosed partnerships limit external validation of scientific quality and credibility

Generated by Claude from Bliss Biopharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BB-1701

Locally Advanced/Metastatic HER2 Positive Solid Tumors

Phase 1

Clinical Trials (1)

NCT04257110A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Phase 1

BB-1709

Solid Tumor

Phase 1

Clinical Trials (1)

NCT06241898A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Phase 1